Tolimidone

Tolimidone (CP-26154; MLR-1023) is a compound which was discovered by scientists at Pfizer, was found to stimulate secretion of gastric mucosa, and was in development by Pfizer as a drug candidate to treat gastric ulcers but was abandoned.[1][2][3] After the patent on the compound expired, scientists at the company Melior Discovery identified it as a potential drug candidate for diabetes through a phenotypic screen and as of 2012 Melior was repurposing it for diabetes.[1][4] In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects[5]

Tolimidone
Clinical data
Other namesCP-26154, MLR-1023
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.230.742
Chemical and physical data
FormulaC11H10N2O2
Molar mass202.21 g/mol g·mol−1
3D model (JSmol)

References
  1. Saporito, Michael S.; Lipinski, Christopher A.; Reaume, Andrew G. (2012). "Chapter 9:Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates". In Barratt, Michael J.; Frail, Donald E. (eds.). Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs. John Wiley & Sons. p. 270. ISBN 9781118274392.
  2. "Tolimidone". AdisInsight. Retrieved 26 August 2017.
  3. Lipinski, C. A.; Stam, J. G.; Pereira, J. N.; Ackerman, N. R.; Hess, H. J. (1980). "Bronchodilator and antiulcer phenoxypyrimidinones". Journal of Medicinal Chemistry. 23 (9): 1026–31. doi:10.1021/jm00183a012. PMID 7411545. Compound 3 has been assigned the nonproprietary (USAN) name tolimidone
  4. "Melior Discovery website press releases".
  5. "Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.